University of Minnesota. Driven to Discover.
A trial at the end of Liberia's Ebola outbreak shows 2 candidate vaccines posed no major safety concerns and triggered immune responses that lasted at least a year.
"I would view the results . . . in an optimistic light," said lead author Richard Davey after the drug showed more than 90% efficacy.
Findings include neurologic problems and a potential for virus survival in semen for 18 months.
Also, phase 2 trials just launched for two prime-boost Ebola vaccine regimens.
The findings clear the way for the next step, which may require a change in venue.
The virus may be more stable than a study in August found.
Other Ebola developments include the departure of Cuba's team from Liberia, new information on evacuee contact monitoring, and outbreak case totals.
Steeply dropping cases, though, may cause the NIAID to vary from the original trial design.
A clinical trial of 2 Ebola vaccine candidates was launched today near Liberia's capital, but falling case numbers may pose problems.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.